Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Russick J, Delignat S, Milanov P, Christophe O, Boros G, Denis CV, Lenting PJ, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jul 9. pii: haematol.2018.210583. doi: 10.3324/haematol.2018.210583. [Epub ahead of print]

2.

Curve fitting problem: torque - velocity relationship with polynomials and Boltzmann sigmoid functions.

Milanov P, Koroleova G, Mavrevski R, Pencheva N.

Acta Bioeng Biomech. 2018;20(1):169-184.

PMID:
29658526
3.

Protein Folding Prediction in a Cubic Lattice in Hydrophobic-Polar Model.

Yanev N, Traykov M, Milanov P, Yurukov B.

J Comput Biol. 2017 May;24(5):412-421. doi: 10.1089/cmb.2016.0181. Epub 2016 Nov 30.

PMID:
27901606
4.

Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.

Quade-Lyssy P, Abriss D, Milanov P, Ungerer C, Königs C, Seifried E, Schüttrumpf J.

J Thromb Haemost. 2014 Nov;12(11):1861-73. doi: 10.1111/jth.12731. Epub 2014 Oct 15.

5.

Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.

Quade-Lyssy P, Milanov P, Abriss D, Ungerer C, Königs C, Seifried E, Schüttrumpf J.

J Thromb Haemost. 2014 Jun;12(6):932-42. doi: 10.1111/jth.12572.

6.

Long-lasting effects of oxy- and sulfoanalogues of L-arginine on enzyme actions.

Dzimbova TA, Milanov PB, Pajpanova TI.

J Amino Acids. 2013;2013:407616. doi: 10.1155/2013/407616. Epub 2013 Oct 24.

7.

Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.

Roth SD, Schüttrumpf J, Milanov P, Abriss D, Ungerer C, Quade-Lyssy P, Simpson JC, Pepperkok R, Seifried E, Tonn T.

PLoS One. 2012;7(9):e44505. doi: 10.1371/journal.pone.0044505. Epub 2012 Sep 4.

8.

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.

Milanov P, Ivanciu L, Abriss D, Quade-Lyssy P, Miesbach W, Alesci S, Tonn T, Grez M, Seifried E, Schüttrumpf J.

Blood. 2012 Jan 12;119(2):602-11. doi: 10.1182/blood-2011-05-353672. Epub 2011 Oct 26.

9.

Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX.

Schüttrumpf J, Milanov P, Abriss D, Roth S, Tonn T, Seifried E.

Hum Gene Ther. 2011 Jan;22(1):101-6. doi: 10.1089/hum.2009.212. Epub 2010 Dec 6.

PMID:
20677911
10.

Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII.

Heinz S, Schüttrumpf J, Simpson JC, Pepperkok R, Nicolaes GA, Abriss D, Milanov P, Roth S, Seifried E, Tonn T.

Thromb Haemost. 2009 Nov;102(5):925-35. doi: 10.1160/TH08-12-0807.

PMID:
19888531
11.

[Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice].

Schüttrumpf J, Milanov P, Roth S, Seifried E, Tonn T.

Hamostaseologie. 2008 Oct;28 Suppl 1:S92-5. German.

PMID:
18958345
12.

Opioid profiles of Cys2-containing enkephalin analogues.

Pencheva N, Milanov P, Vezenkov L, Pajpanova T, Naydenova E.

Eur J Pharmacol. 2004 Sep 13;498(1-3):249-56.

PMID:
15364002
13.

Activity profiles of dalargin and its analogues in mu-, delta- and kappa-opioid receptor selective bioassays.

Pencheva N, Pospisek J, Hauzerova L, Barth T, Milanov P.

Br J Pharmacol. 1999 Oct;128(3):569-76.

14.

Comparison of gamma-aminobutyric acid effects in different parts of the cat ileum.

Pencheva N, Itzev D, Milanov P.

Eur J Pharmacol. 1999 Feb 26;368(1):49-56.

PMID:
10096769

Supplemental Content

Loading ...
Support Center